PT-141 (Bremelanotide): what it is and what the evidence says
A peptide studied for its relationship with melanocortin pathways in the central nervous system, associated with sexual-desire response. It mainly activates the MC4R receptor in the hypothalamus, and the FDA approved it in 2019 for hypoactive sexual desire in premenopausal women.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Hormones work in axes: a signal from the brain tells a gland to release another hormone, and so on down the chain, with brakes that shut the process off. Intervening at one point has consequences both upstream and downstream. That is why this is the group where professional assessment stops being a recommendation and becomes essential.
What it is studied for
Libido, sexual response (male and female).
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
Two randomized, placebo-controlled phase 3 trials (the RECONNECT program, 1,247 premenopausal women, 24 weeks) showed more desire and less distress than placebo and led to its FDA approval in 2019. A 52-week open-label extension followed 684 participants; in men there are phase 2 trials with the nasal form.
The limitation that matters most
The average advantage over placebo is moderate and its clinical relevance is debated in the literature; the number of satisfying sexual events did not change. Nausea affects close to 40% of users, and large trials in men and in women after menopause are still missing.
Regulatory status
Approved by the FDA in 2019 (Vyleesi, now owned by Cosette Pharmaceuticals) for acquired, generalized hypoactive sexual desire disorder in premenopausal women; it is not indicated in men or after menopause. We found no EMA authorization. It is not listed by name on the 2026 WADA Prohibited List.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
It can raise blood pressure transiently and lower the pulse slightly, so the cardiovascular profile matters. Nausea is common and, with applications placed very close together, it can darken the skin.
With cardiovascular conditions or altered pressure, medical assessment is mandatory.
What this page cannot give you
A reference page can take you this far. You know what PT-141 (Bremelanotide) is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.human Obstet Gynecol · 2019 · PMID 31599840 →
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.human Obstet Gynecol · 2019 · PMID 31599847 →
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.human J Womens Health (Larchmt) · 2022 · PMID 35230162 →
- The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.human J Womens Health (Larchmt) · 2021 · PMID 33538638 →
- Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.human J Sex Med · 2019 · PMID 31277966 →
- Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.review J Sex Res · 2024 · PMID 36809187 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for PT-141 (Bremelanotide) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is PT-141 (Bremelanotide)?
A peptide studied for its relationship with melanocortin pathways in the central nervous system, associated with sexual-desire response. It mainly activates the MC4R receptor in the hypothalamus, and the FDA approved it in 2019 for hypoactive sexual desire in premenopausal women. It is studied within the area of hormonal/sexual.
Is there human evidence for PT-141 (Bremelanotide)?
Two randomized, placebo-controlled phase 3 trials (the RECONNECT program, 1,247 premenopausal women, 24 weeks) showed more desire and less distress than placebo and led to its FDA approval in 2019. A 52-week open-label extension followed 684 participants; in men there are phase 2 trials with the nasal form.
Is it approved by any health agency?
Approved by the FDA in 2019 (Vyleesi, now owned by Cosette Pharmaceuticals) for acquired, generalized hypoactive sexual desire disorder in premenopausal women; it is not indicated in men or after menopause. We found no EMA authorization. It is not listed by name on the 2026 WADA Prohibited List.
What is the dose of PT-141 (Bremelanotide)?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what PT-141 (Bremelanotide) is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.